31542-52-6

Basic information

• Product Name: 8-bromo-1,3-diethyl-3,7-dihydro-1H-purine-2,6-dione
• CAS NO: 31542-52-6
• Molecular Formula: C₉H₁₁BrN₄O₂
• Molecular Weight: 287.1132
• Mol File: 31542-52-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 471.9°C at 760 mmHg
• Flash Point: 239.2°C
• Density: 1.647g/cm³
• Vapor Pressure: 4.47E-09mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: 8-bromo-1,3-diethyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-bromo-1,3-diethyl-3,7-dihydro-1H-purine-2,6-dione(31542-52-6)
• EPA Substance Registry System: 8-bromo-1,3-diethyl-3,7-dihydro-1H-purine-2,6-dione(31542-52-6)

Safety Data

• Hazardous Substances Data: 31542-52-6(Hazardous Substances Data)

Upstream product

• 89073-60-9 6-amino-1,3-diethyl-5-nitroso-1H,3H-pyrimidine-2,4-dione 
• 52998-22-8 5,6-diamino-1,3-diethyluracil 
• 41740-15-2 6-amino-1,3-diethyluracil 
• 623-76-7 N,N'-diethylurea 
• 454710-33-9 7-benzyl-1,3-diethyl-1,3,7-trihydropurine-2,6-dione 
• 5169-95-9 1,3-diethylxanthine 

Downstream Products

• 865452-37-5 8-bromo-1,3-diethyl-7-(4-hydroxy-benzyl)-3,7-dihydro-purine-2,6-dione 
• 865452-36-4 8-bromo-1,3-diethyl-7-(4-methoxy-benzyl)-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B

Annelated purinedione derivatives have been shown to act as possible multiple-target ligands, addressing adenosine receptors and monoaminooxidases. In this study, based on our previous results, novel annelated pyrimido- and diazepino[2,1-f]purinedione derivatives were designed as dual-target-directed ligands combining A2A adenosine receptor (AR) antagonistic activity with blocking monoamine oxidase B. A library of 19 novel compounds was synthesized and biologically evaluated in radioligand binding studies at AR subtypes and for their ability to inhibit MAO-B. This allowed 9-(2-chloro-6-fluorobenzyl)-3-ethyl-1-methyl-6,7,8,9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (13 e; Ki human A2AAR: 264 nM and IC50 human MAO-B: 243 nM) to be identified as the most potent dual-acting ligand from this series. ADMET parameters were estimated in vitro, and analysis of the structure-activity relationships was complemented by molecular-docking studies based on previously published X-ray structures of the protein targets. Such dual-acting ligands, by selectively blocking A2A AR, accompanied by the inhibition of dopamine metabolizing enzyme MAO-B, might provide symptomatic and neuroprotective effects in, among others, the treatment of Parkinson disease.